I have been under Dr Verter's care for a couple years after a torn retina. He and his team in Westport have been rockstars! Kudos to all!!! 👏👏👏👏
When to Refer Diabetic Patients for Retina Care
Understanding Diabetic Retinopathy
Diabetic retinopathy develops when chronically high blood sugar damages the tiny blood vessels inside the eye. Understanding how and why this happens is the foundation for knowing when and why referral to a retina specialist matters.
Diabetic retinopathy is damage to the blood vessels in the retina, the light-sensitive layer of tissue lining the back of the eye, caused by prolonged high blood sugar. Over time, elevated glucose levels weaken and alter these tiny vessels. They may leak fluid, swell, or close off entirely, depriving the retina of the oxygen and nutrients it needs to function properly.
Chronic high blood sugar injures the walls of retinal blood vessels, triggering inflammation and the release of a protein called vascular endothelial growth factor, or VEGF. VEGF signals the eye to grow new blood vessels, but these new vessels are fragile and prone to leaking blood or fluid. Over time, scar tissue can form, creating traction on the retina that raises the risk of retinal detachment, a condition in which the retina separates from the back of the eye.
Diabetic retinopathy progresses through two broad stages. The earlier stage, nonproliferative diabetic retinopathy (NPDR), involves changes such as small bulges in blood vessel walls called microaneurysms, areas of bleeding in the retina, and vessel swelling. Abnormal new blood vessel growth has not yet begun at this stage.
The more advanced stage, proliferative diabetic retinopathy (PDR), occurs when the retina becomes so deprived of oxygen that the eye begins growing new, abnormal blood vessels. These fragile vessels can bleed into the vitreous, the clear gel that fills the inside of the eye, and may lead to serious complications including retinal detachment.
Diabetic macular edema, or DME, is swelling in the macula, the small central area of the retina responsible for sharp, detailed vision. DME can occur at any stage of diabetic retinopathy. When fluid leaks into the macula, it blurs or distorts central vision. Center-involved DME, where swelling affects the very center of the macula, poses the greatest risk to tasks such as reading, driving, and recognizing faces.
Who Is Affected and Why
Diabetic retinopathy is common, and certain factors significantly increase a person's risk of developing it. Knowing these risk factors helps providers identify patients who need earlier or more frequent retinal screening.
A large proportion of people living with diabetes will develop some degree of retinopathy over time. Studies suggest that approximately one in four people with diabetes in the United States has some form of the condition, and among those, a meaningful percentage have vision-threatening disease. Perhaps most important for screening purposes is that nearly one in four people newly diagnosed with diabetes may already have signs of retinopathy at the time of diagnosis, even before any symptoms appear.
Several medical factors make it more likely that a person with diabetes will develop retinopathy or experience faster progression. Providers and patients should keep these in mind when determining how often retinal exams are needed.
- Duration of diabetes: people who have had diabetes for 15 years or more are significantly more likely to have retinopathy, and far more likely to have severe disease, compared to those who were recently diagnosed
- Chronic high blood sugar (poor glycemic control)
- High blood pressure (hypertension)
- High cholesterol and other abnormalities in blood fats (dyslipidemia)
- Kidney disease (nephropathy)
Pregnant women with pre-existing diabetes face an increased risk of rapid disease progression. These patients should receive a retinal exam early in pregnancy and be monitored closely throughout. Women who develop gestational diabetes, a form of diabetes that begins during pregnancy, do not require a separate eye exam for that condition alone.
Adolescents going through puberty may also experience faster progression of retinopathy, making closer follow-up important during this period. The possibility that signs of retinopathy are already present at the time of a diabetes diagnosis further underscores why the first retinal exam should not be delayed.
There is growing evidence that rapid, aggressive improvement in blood sugar levels may accelerate the early development of diabetic retinopathy in some patients. This effect has been observed with newer glucose-lowering medications. Patients beginning these treatments, particularly those who previously had elevated blood sugar levels, may benefit from a baseline retinal evaluation and closer monitoring during the first year of use. Providers should consider coordinating with a retina specialist when initiating this type of therapy.
Recognizing the Signs and Symptoms
One of the most challenging aspects of diabetic retinopathy is that it often causes no symptoms in its early stages. Knowing what to look for, and what to do when certain symptoms appear, can help prevent serious vision loss.
In the early phase of diabetic retinopathy, most patients have no noticeable change in their vision. Damage can accumulate silently inside the eye for months or even years before any symptom develops. This is one of the most compelling reasons for routine retinal screening, even when a patient reports that their vision feels completely fine.
As the disease advances, patients may begin to notice changes in their vision. These can include blurred or fluctuating sight, dark spots or floaters (small shapes that drift through the field of vision), difficulty seeing in low light, and colors that appear faded or washed out. When diabetic macular edema is present, straight lines may appear wavy and reading or close-up tasks may become more difficult.
Certain symptoms suggest a potentially sight-threatening emergency and should not be ignored. A sudden, significant increase in floaters, flashes of light, a dark shadow or curtain appearing across part of the vision, or sudden vision loss in one eye all require immediate evaluation. These symptoms may indicate a vitreous hemorrhage, meaning bleeding inside the eye, or a retinal detachment, both of which need prompt treatment to protect vision.
Diagnosis and Screening
Accurate diagnosis of diabetic retinopathy depends on regular screening and, when needed, advanced imaging. The earlier the disease is detected, the more treatment options are available and the more vision can typically be preserved.
People with type 1 diabetes should begin annual retinal screenings five years after their diagnosis. People with type 2 diabetes should have their first exam at the time of diagnosis and at least once every year afterward. A retina specialist may recommend more frequent visits depending on what is found during an examination.
The standard method for detecting diabetic retinopathy is a comprehensive dilated eye exam. The retina specialist uses drops to widen the pupil so the back of the eye can be clearly seen. During the exam, the specialist looks for microaneurysms, retinal bleeding, swelling, abnormal blood vessel growth, and other structural changes that indicate disease activity.
In addition to the dilated exam, retina specialists may use specialized imaging tools to evaluate the retina in greater detail and guide treatment decisions.
- Optical coherence tomography (OCT): creates detailed cross-sectional images of the retina to measure swelling and detect fluid accumulation
- OCT angiography (OCT-A): a non-invasive imaging technique that maps blood flow in the retina without the need for injected dye
- Fluorescein angiography: uses a dye injected into a vein to reveal leaking or blocked blood vessels in the retina
- Wide-field imaging: allows visualization of a much larger area of the retina than traditional photography, which is especially useful for detecting disease at the periphery
- Electroretinography (ERG): measures the electrical response of the retina to light and is included in updated clinical guidelines for evaluating diabetic retinopathy
Treatment Options for Diabetic Retinopathy
Treatment for diabetic retinopathy has advanced considerably in recent years. The right approach depends on the stage of the disease, whether macular edema is present, and the individual needs and circumstances of each patient.
Anti-VEGF medications are the primary treatment for center-involved diabetic macular edema with vision loss and for proliferative diabetic retinopathy. These drugs work by blocking VEGF, the protein responsible for driving abnormal blood vessel growth and leakage. They are delivered as intravitreal injections, meaning they are given directly into the eye after numbing drops are applied.
Several anti-VEGF agents are used in retina care. Aflibercept (Eylea) is among the most widely used, typically given every four to eight weeks after initial loading doses. A higher-dose formulation (Eylea HD) allows dosing intervals of up to five months for some eligible patients with DME. Ranibizumab (Lucentis) was the first anti-VEGF agent approved specifically for use in the eye and is typically given every four weeks. Faricimab (Vabysmo) targets both VEGF and a second pathway involved in vascular leakage and can be administered at intervals of up to 16 weeks for some patients.
Bevacizumab (Avastin) is FDA-approved for the treatment of certain cancers but is widely used off-label by retina specialists for diabetic macular edema and diabetic retinopathy. It works through the same VEGF-blocking mechanism as other anti-VEGF agents and is typically administered every four to six weeks. Patients should understand that its use for retinal conditions is off-label, meaning it has not received specific FDA approval for this purpose, though it has a well-established track record in retina care.
A refillable implant called Susvimo (ranibizumab injection, 100 mg/mL) offers a continuous medication delivery option for some patients with diabetic retinopathy. The small device is surgically placed in the eye and releases medication continuously, with refills needed approximately every nine months. This approach may reduce the number of office visits required for ongoing treatment, which can be an important consideration for some patients.
Panretinal photocoagulation (PRP) remains an important treatment for proliferative diabetic retinopathy. During PRP, a retina specialist applies hundreds of small laser burns to the peripheral retina, which reduces the retina's demand for oxygen and slows the growth of abnormal blood vessels. In some cases of diabetic macular edema, focal or grid laser therapy may also be considered as part of the overall treatment plan.
Vitrectomy is a surgical procedure to remove the vitreous gel from inside the eye. It may be needed when there is significant bleeding into the vitreous or when scar tissue creates traction on the retina. The retina specialist removes the vitreous along with any blood or scar tissue and replaces it with a clear solution or a gas bubble to support retinal healing. This procedure is typically reserved for cases where other treatment options are not sufficient to address the extent of the disease.
What to Expect from Care
Understanding what treatment involves, and what can realistically be expected, helps patients and their families feel more prepared and confident throughout the process.
When diabetic retinopathy is detected and treated early, current treatment strategies can be highly effective at preventing severe vision loss. Anti-VEGF injections can stabilize the disease and, in some cases, lead to measurable improvement in retinal appearance and visual function. Outcomes depend significantly on how advanced the condition is when treatment begins, which is one of the strongest arguments for early referral and consistent monitoring.
Most anti-VEGF treatment visits take less than an hour. The eye is numbed with anesthetic drops before each injection, so patients typically feel mild pressure rather than sharp pain. Some redness, soreness, or a gritty sensation after the injection is normal and usually resolves within a day or two. Ongoing treatment requires regular follow-up visits for imaging, monitoring of vision, and additional injections as determined by the retina specialist.
Diabetic retinopathy is a chronic condition. Even after successful treatment, the disease can recur or progress over time, particularly if blood sugar or blood pressure are not well controlled. Regular follow-up exams allow the retina specialist to detect new activity early and adjust the treatment plan before additional vision is affected. The appropriate follow-up schedule is determined based on each patient's disease severity and individual response to treatment.
Living with Diabetic Retinopathy
Managing diabetic retinopathy effectively extends beyond clinic visits. Daily choices and consistent engagement with care have a meaningful impact on long-term vision outcomes.
Controlling blood sugar is one of the most powerful steps a person with diabetes can take to slow the progression of retinopathy. Working closely with a primary care provider or endocrinologist to maintain healthy blood glucose, blood pressure, and cholesterol levels directly supports retinal health. These systemic efforts complement the treatments provided by a retina specialist and can meaningfully influence how the disease behaves over time.
Because diabetic retinopathy can worsen without any noticeable symptoms, skipping or delaying scheduled eye exams can allow the disease to advance to a stage where treatment is less effective. Patients should keep all scheduled appointments and contact their retina specialist promptly if they notice any new changes in their vision, rather than waiting until the next scheduled visit.
A diagnosis of diabetic retinopathy can feel frightening, particularly for patients who are already managing the daily challenges of diabetes. Many patients find it helpful to connect with diabetes support groups or, if their sight has been affected, with low-vision rehabilitation services. Asking questions during appointments and understanding the reasoning behind treatment decisions can help patients feel more involved and less anxious about their care.
When to Refer to a Retina Specialist
Primary care providers and optometrists are often the first clinicians to identify signs of diabetic retinopathy. Knowing which findings require referral, and how urgently, is essential to protecting patient vision.
The following findings on a dilated exam or retinal imaging should prompt referral to a retina specialist for further evaluation and management.
- Any level of macular edema detected on exam or imaging
- Severe nonproliferative diabetic retinopathy, which is a precursor to the proliferative stage
- Any degree of proliferative diabetic retinopathy, including the presence of new abnormal blood vessels
- Visual acuity worse than 20/40, or patient-reported symptomatic vision changes
- Neovascularization of the iris or angle (new blood vessel growth at the front of the eye), which requires urgent referral
Not all referrals carry the same level of urgency. High-risk proliferative diabetic retinopathy, defined by extensive new vessel growth on the optic disc or any new vessel growth accompanied by vitreous hemorrhage, warrants referral within 24 to 48 hours. Lower-risk proliferative disease may be referred within two to four weeks. Anterior segment neovascularization, meaning new vessel growth in the front part of the eye, requires urgent evaluation because prompt treatment may prevent neovascular glaucoma, a severe complication involving dangerously elevated eye pressure that can cause irreversible damage to the optic nerve.
Some patients benefit from more frequent retinal evaluations beyond the standard annual schedule. These include pregnant women with pre-existing diabetes, adolescents going through puberty, patients beginning rapid glucose-lowering therapies, and those with a history of poor blood sugar control or long-standing diabetes. When there is uncertainty about the appropriate interval, referring for a baseline evaluation at a retina specialist's office is a reasonable and proactive approach.
Frequently Asked Questions
Here are answers to some of the questions we hear most often from patients and referring providers when navigating a diabetic retinopathy diagnosis or referral decision.
Yes, and this is one of the most critical points to communicate to patients. Significant retinal changes can develop silently, long before a person notices any difference in their sight. By the time symptoms do appear, the disease may already be at an advanced stage where treatment options are more limited. This is exactly why keeping up with annual dilated eye exams matters so much, even for patients who feel their vision is currently unaffected.
The pace of progression varies considerably from person to person. Some individuals may have mild disease that remains stable for many years. Others can advance to a vision-threatening stage within months, particularly when blood sugar, blood pressure, or cholesterol are poorly managed. Pregnancy, puberty, and rapid changes in blood sugar levels can all accelerate the timeline. Regular monitoring by a retina specialist is the most reliable way to catch changes before they become more difficult to treat.
Many patients are relieved to find the injections more manageable than expected. The eye is thoroughly numbed with anesthetic drops before each injection, so the sensation during the procedure is typically mild pressure rather than sharp pain. Some redness, soreness, or a gritty feeling afterward is normal and usually clears up within a day or two. Patients who feel anxious about the procedure are encouraged to discuss their concerns with their retina specialist beforehand so expectations can be set clearly.
Without treatment, diabetic retinopathy can lead to permanent and severe vision loss. Proliferative disease can result in vitreous hemorrhage, scar tissue formation, and retinal detachment, all of which can cause irreversible damage if not addressed promptly. Diabetic macular edema can progressively destroy the central vision needed for everyday tasks like reading and recognizing faces. Early referral and consistent treatment offer the best chance of preserving functional vision over the long term.
This is a question we are hearing with increasing frequency. Rapid improvement in blood sugar control, including from certain newer glucose-lowering medications, may trigger earlier progression of diabetic retinopathy in some patients, particularly those who have had elevated glucose levels for an extended period. We may recommend a baseline retinal evaluation before starting these medications and closer follow-up during the initial phase of treatment. Coordinating between a patient's diabetes care team and their retina specialist helps ensure that both metabolic and retinal health are managed together rather than in isolation.
Schedule a Consultation at New England Retina Associates
If you or a patient in your care has signs of diabetic retinopathy, or has not had a recent retinal evaluation, our team at New England Retina Associates is here to help. We welcome both referred and self-referred patients, offer comprehensive retinal evaluation and treatment at all four of our Connecticut offices, and are experienced in managing the full spectrum of diabetic eye disease. Reach out to us to schedule an appointment and take an important step toward protecting your vision.
30 Years of Care & Commitment
